Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry, **RAB28, member RAS oncogene family pseudogene 3 (RAB28P3)**, is classified as a *pseudogene* in Homo sapiens. It is not a protein-coding gene and has no known biological function, disease association, or role as a therapeutic target. There are no known aliases, interacting drugs, or safety concerns, and it should not be considered a conventional molecular target for therapeutic intervention[1][5][6][7]. **Note:** This entry is a *pseudogene* and not a functional target molecule or receptor. If you are seeking information on an active member of the RAB GTPase family, please refer to the canonical protein-coding gene (e.g., **RAB28**) and not the pseudogene variant (RAB28P3)[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAB28, member RAS oncogene family pseudogene 3 (RAB28P3).